Bustos GÁ

Idioma: Español
Referencias bibliográficas: 21
Paginas: 109-113
Archivo PDF: 167.58 Kb.

RESUMEN

Los antibióticos beta-lactámicos son parte de los medicamentos más frecuentemente utilizados y se agrupan con base en su estructura común, el anillo beta-lactámico. Las cefalosporinas parenterales cubren un amplio rango de microorganismos, son bien toleradas en general y fáciles de administrar. Aquí se revisa su clasificación, espectro de actividad y farmacología.

REFERENCIAS (EN ESTE ARTÍCULO)

1. http://www.fda.gov/Drugs/DrugSafety

2. Mulligan ME, et al. MRSA: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993; 94:313- 328.

3. Tomasz A. Antibiotic resistance in S. pneumoniae. Clin Infect Dis 1997; 24 Suppl 1:S85-S88.

4. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant S. pneumoniae. N Engl J Med 1994; 331:337-382.

5. Whitney CG, et al. Increasing prevalence of multidrugresistant S. pneumoniae in the United States. N Engl J Med 2000; 343:1917-1924.

6. Sabath LD. Reappraisal of the antistaphylococcal activities of first-generation and second-generation cephalosporins. Antimicrob Agents Chemother 1989; 33:407-411.

7. Pitout JD, et al. Antimicrobial resistance with focus on betalactam resistance in Gram negative bacilli. Am J Med 1997; 103:51-59.

8. Schaad UB, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990; 322:141-147.

9. Bohnen JM, et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 1992; 127:83-89.

10. Wexler HM, Finegold SM. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother 1988; 32:601-604.

11. Snydman DR, et al. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroidesfragilis group species from 1990 to 1994. Clin Infect Dis 1996; 23 Suppl 1: S54-65.

12. Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am 1995; 79:705-719.

13. Steere AC. Lyme disease. N Engl J Med 1989; 321:586- 596.

14. Shiffman ML, et al. Pathogenesis of ceftriaxone-associated biliary sludge. In-vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990; 99:1772-1778.

15. Sattler FR, et al. Potential for bleeding with the new betalactam antibiotics. Ann Intern Med 1986; 105:924-931.

16. Sanders WE, et al. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996; 23:454-461.

17. Yahav D, et al. Efficacy and safety of cefepime: a systematic review and meta-analisis. Lancet Infect Dis 2007; 7:338-348.

18. Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.ClinMicrobiol Infect 2007; 13 Suppl 2:25-29.

19. Bush K, et al. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy: Expert Opin Investig Drugs 2007; 16:419-429.

20. Willems RJ, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11:821-828.

21. Bogdanovich T, et al. Antistaphylococcal activity of ceftobiprole, a new broad spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49:4210-4219.